{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Patient&page=64",
    "query": {
      "condition": "Patient",
      "page": 64
    },
    "page_size": 10
  },
  "pagination": {
    "page": 64,
    "page_size": 10,
    "total_count": 54948,
    "total_pages": 5495,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Patient&page=65&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Patient&page=63&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T09:27:35.735Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01054729",
      "title": "Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PEG",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "2010-01",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2014-04-17",
      "last_synced_at": "2026-11-09T09:27:35.735Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01054729"
    },
    {
      "nct_id": "NCT00762229",
      "title": "Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Ezetimibe 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe 5 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bronx VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2007-07",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2013-06-14",
      "last_synced_at": "2026-11-09T09:27:35.735Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00762229"
    },
    {
      "nct_id": "NCT02198131",
      "title": "Pulsed Dye Laser in Treating Patients With Post Radiation Dysphonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Oral Complications of Radiation Therapy",
        "Stage I Laryngeal Cancer",
        "Stage II Laryngeal Cancer"
      ],
      "interventions": [
        {
          "name": "laser therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 9,
      "start_date": "2009-10",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2023-04-26",
      "last_synced_at": "2026-11-09T09:27:35.735Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02198131"
    },
    {
      "nct_id": "NCT05350072",
      "title": "Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sjogren Syndrome"
      ],
      "interventions": [
        {
          "name": "VAY736",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 275,
      "start_date": "2022-07-28",
      "completion_date": "2026-06-02",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-11-09T09:27:35.735Z",
      "location_count": 13,
      "location_summary": "Van Nuys, California • Tamarac, Florida • Indianapolis, Indiana + 10 more",
      "locations": [
        {
          "city": "Van Nuys",
          "state": "California"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05350072"
    },
    {
      "nct_id": "NCT04742595",
      "title": "Viral Specific T Cell Therapy for COVID-19 Related Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm",
        "Symptomatic COVID-19 Infection Laboratory-Confirmed"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2020-12-18",
      "completion_date": "2024-09-20",
      "has_results": false,
      "last_update_posted_date": "2024-10-29",
      "last_synced_at": "2026-11-09T09:27:35.735Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04742595"
    },
    {
      "nct_id": "NCT05950295",
      "title": "Intranasal Lavage With Hypochlorous Acid Safely Reduces the Symptoms in the Ambulatory Patient With COVID-19.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Intranasal lavage with hypochlorous acid solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Monique Lisa Abner",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2020-09-24",
      "completion_date": "2021-04-13",
      "has_results": false,
      "last_update_posted_date": "2023-07-18",
      "last_synced_at": "2026-11-09T09:27:35.735Z",
      "location_count": 1,
      "location_summary": "Reading, Pennsylvania",
      "locations": [
        {
          "city": "Reading",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05950295"
    },
    {
      "nct_id": "NCT06458439",
      "title": "Epcoritamab-CAR T Cells for Large B-cell Lymphomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Relapsed Diffuse Large B Cell Lymphoma",
        "Refractory Diffuse Large B-cell Lymphoma",
        "High-grade B-cell Lymphoma",
        "Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Epcoritamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2024-09-24",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-11-09T09:27:35.735Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06458439"
    },
    {
      "nct_id": "NCT03176277",
      "title": "A Study of ONO-7475 in Patients With Acute Leukemias",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "ONO-7475 3mg once daily",
          "type": "DRUG"
        },
        {
          "name": "ONO-7475 6mg once daily",
          "type": "DRUG"
        },
        {
          "name": "ONO-7475 10mg once daily",
          "type": "DRUG"
        },
        {
          "name": "ONO-7475 6mg + Venetoclax (70-400mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ono Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2017-06-26",
      "completion_date": "2023-01-20",
      "has_results": true,
      "last_update_posted_date": "2024-07-15",
      "last_synced_at": "2026-11-09T09:27:35.735Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • North Haven, Connecticut • Gainesville, Florida + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "North Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03176277"
    },
    {
      "nct_id": "NCT00268957",
      "title": "Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Diseases",
        "Chronic Renal Insufficiency",
        "End-Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Sevelamer carbonate (Renvela®)",
          "type": "DRUG"
        },
        {
          "name": "Sevelamer hydrochloride (Renagel®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 217,
      "start_date": "2006-01",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2014-03-19",
      "last_synced_at": "2026-11-09T09:27:35.735Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Gadsden, Alabama • Mission Hills, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gadsden",
          "state": "Alabama"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        },
        {
          "city": "Crystal River",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00268957"
    },
    {
      "nct_id": "NCT00585559",
      "title": "Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Aneurysmal Subarachnoid Hemorrhage",
        "Cerebral Vasospasm"
      ],
      "interventions": [
        {
          "name": "Placebos for acetaminophen and N-acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "APAP 1 gm every 6 hours and N-acetylcysteine placebo",
          "type": "DRUG"
        },
        {
          "name": "NAC IV infusion at 0.5 gm hourly and APAP placebo",
          "type": "DRUG"
        },
        {
          "name": "APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly",
          "type": "DRUG"
        },
        {
          "name": "APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2007-04",
      "completion_date": "2023-10-26",
      "has_results": true,
      "last_update_posted_date": "2025-04-18",
      "last_synced_at": "2026-11-09T09:27:35.735Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00585559"
    }
  ]
}